Oral Anticoagulation and Mortality in Cases with Intracranial Bleeding: Analysis of Nationwide Prescription and Hospitalization Data
CONCLUSION: LUA seems to be safe because there is a slower increase of the rate of LUAs in ICB cases than in generally hospitalized cases in the period from 2006 to 2020. In addition, mortality in ICB cases with LUA tends to decrease compared to cases without LUA.PMID:38316418 | DOI:10.1055/a-2229-8047 (Source: Hamostaseologie)
Source: Hamostaseologie - February 5, 2024 Category: Hematology Authors: Knut Kr öger Fabian Heldt Ludger Feyen Kathrin Feller Bernd Kowall Andreas Stang Source Type: research
Prognostic impact of CEBPA mutational subgroups in adult AML
In conclusion, these results demonstrate bZIPInDel mutations to be the major independent determinant of outcome in CEBPA-mutant AML, thereby refining current classifications according to WHO (including all dmCEBPA and smCEBPA bZIP) as well as ELN2022 and ICC recommendations (including CEBPA bZIPms).PMID:38228680 | PMC:PMC10844079 | DOI:10.1038/s41375-024-02140-x (Source: Hamostaseologie)
Source: Hamostaseologie - January 16, 2024 Category: Hematology Authors: Julia-Annabell Georgi Sebastian Stasik Michael Kramer Manja Meggendorfer Christoph R öllig Torsten Haferlach Peter Valk David Linch Tobias Herold Nicolas Duployez Franziska Taube Jan Moritz Middeke Uwe Platzbecker Hubert Serve Claudia D Baldus Carsten Mu Source Type: research
Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis
Hamostaseologie. 2024 Jan 15. doi: 10.1055/a-2212-1565. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) represents a worldwide health challenge, impacting millions of people each year. The genesis of venous thrombosis is influenced in part by genetic components. Hereditary thrombosis is described as a genetically determined susceptibility to VTE. In the present study, a male patient was referred to our department presenting with multiple venous thrombosis events in different locations. Given a lack of identifiable risk factors, we aimed to investigate the possible genetic factor underlying venous thrombosis. Who...
Source: Hamostaseologie - January 15, 2024 Category: Hematology Authors: Xiangui Li Jiabao Zhu Fanzhen Lv Wenqi Ma Weimin Zhou Wenwen Zhang Source Type: research
Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies
Hamostaseologie. 2024 Jan 8. doi: 10.1055/a-2215-9909. Online ahead of print.ABSTRACTThromboembolic complications, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), increase mortality and morbidity, and delay treatment in patients with cancer. Therefore, an increased understanding of underlying risk profiles, the identification of risk factors and predictive biomarkers, and ultimately the development of specific cardiovascular prevention strategies in patients with cancer is needed. Medical anticancer therapies have undergone a remarkable development in recent years with the advent of targeted and ...
Source: Hamostaseologie - January 8, 2024 Category: Hematology Authors: Florian Moik Jakob M Riedl Cornelia Englisch Cihan Ay Source Type: research
Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies
Hamostaseologie. 2024 Jan 8. doi: 10.1055/a-2215-9909. Online ahead of print.ABSTRACTThromboembolic complications, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), increase mortality and morbidity, and delay treatment in patients with cancer. Therefore, an increased understanding of underlying risk profiles, the identification of risk factors and predictive biomarkers, and ultimately the development of specific cardiovascular prevention strategies in patients with cancer is needed. Medical anticancer therapies have undergone a remarkable development in recent years with the advent of targeted and ...
Source: Hamostaseologie - January 8, 2024 Category: Hematology Authors: Florian Moik Jakob M Riedl Cornelia Englisch Cihan Ay Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management
Hamostaseologie. 2023 Dec 20. doi: 10.1055/a-2202-8620. Online ahead of print.ABSTRACTFactor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evid...
Source: Hamostaseologie - December 20, 2023 Category: Hematology Authors: Andreas Verstraete Matthias M Engelen Charlotte Van Edom Thomas Vanassche Peter Verhamme Source Type: research
